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Sensitivity to environmental chemicals in
general, and in particular to volatile organ-
ic chemicals (VOCs) in indoor air, needs
to be elucidated. The lack of an estab-
lished mechanism to explain how exposure
to concentrations of VOCs that are well
tolerated by the population at large can
produce the array of symptoms seen in
sensitized individuals has hampered pro-
gress in understanding these disorders.
Over the past few years progress has been
made in understanding neurogenic in-
flammation, chemical irritant receptors,
and the regulation of neurogenic inflam-
mation. Here I review these topics,
emphasizing those aspects that may be
applicable to elucidating the mechanism
ofchemical sensitivity as a disorder ofthe
regulation of neurogenic inflammation.
Possible application to specific clinical
entities is discussed, with suggestions for
clinical research to study the association.
Neurogenic Inflammation
Inflammation is an abnormal condition of
redness, swelling, heat, and pain localized
to a tissue. Histologically, inflammation
is characterized by edema, vasodilatation,
and infiltrates ofleukocytes. A number of
chemical mediators of inflammation have
been identified biochemically. Inflam-
mation may be triggered by the immune
system, in which foreign materials interact
with leukocyte receptors created after a
sensitizing exposure to trigger an inflam-
matory cascade. Neurogenic inflamma-
tion is a well-defined process by which
inflammation is triggered by the nervous
system.
Early in the study of neurogenic in-
flammation, chemical stimulation was rec-
ognized as a trigger of neurogenic inflam-
mation. As early as 1910, it was recog-
nized that the application of mustard oil
to the conjunctival sac in experimental
models produces inflammation that can be
blocked by sensory nerve ablation (1,2).
The neuropeptides substance P (SP), neu-
rokinen A (NA), and calcitonin gene-relat-
ed peptide (CGRP) are now known to
coexist in sensory neurons and to have
potent vasodilatory properties (3-6).
Direct stimulation of sensory nerves pro-
duces vasodilatation (7,8), which can be
blocked by depletion of substance P with
capsaicin (9-11). The sensory fibers
involved in neurogenic inflammation have
been identified as C-fibers with a slow
velocity of1-2 m/sec (14.
Progress has been made in understand-
ing the regulation of neurogenic inflam-
mation (13). A cell-surface enzyme, neu-
tral endopeptidase (NEP), downregulates
neurogenic inflammation by degradating
substance P. In the lung this enzyme is
inhibited by cigarette smoke, viral infec-
tions, and toluene diisocynate, whereas
corticosteroids increase NEP.
Neurogenic inflammation is now a
well-defined physiological mechanism by
which mediators are directly released from
sensory nerves to produce-vasodilatation,
edema, and other manifestations of in-
flammation. The nerve fibers have been
identified as slow velocity C-fibers, and
the regulation ofneurogenic inflammation
has been studied.
Chemical Irritant Receptors
The common chemical sense is a nasal
sensation provoked by airborne chemicals
which is distinct from taste and smell
(14). This sense is experienced as a burn-
ing and painfil sensation in the upper air-
ways and eyes upon exposure to irritant
Figure 1. Olfaction and the common chemical sense. Olfaction is the sensation of odor, transmitted by
cranial nerve 1,the olfactory nerve. The common chemical sense is a sensation of burning and irritation
inthe airway, produced byirritantchemicals andtransmitted by cranial nerveV,thetrigeminal nerve.
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Figure 2 Schematc diagram of neurogenic inflammation triggered by chemical irritants. Chemical irri-
tants (C) bind chemical irritant receptors on sensory nerves to release substance P (P) and other media-
tors from nerve endings. Substance P binds receptors on effector cellstotrigger inflammation. Neutral
endopeptidase (nep), an enzyme located on the membranes of effector cells, degrades substance P and
downregulates neurogenic inflammation. It is proposed that chemical sensitivity syndromes are disor-
ders ofthe regulation ofneurogenic inflammation.
substances and results from exposure of
trigeminal nerve endings to the irritants.
The skin and other mucous membranes
have similar responses to irritant chemi-
cals. Recent studies in anosmic subjects
have separated the common chemical
sense from olfaction (15). The common
chemical sense and olfaction are depicted
in Figure 1. There is evidence that pro-
tein receptors on cell membranes are the
activation site for chemical irritants. It is
thought that sensory nerves act as both
afferent and efferent nerves for neurogenic
inflammation triggered by chemical irri-
tants. In the nose, substance P release has
been verified for exposures to nicotine,
capsaicin, ether, formaldehyde, and ciga-
rette smoke (16,17). Hence, stimulation
of the chemical irritant receptors leads to
neurogenic inflammation. The relation-
ship among chemical irritants, sensory
nerves, substance P, and NEP is summa-
rized in Figure 2.
Regulation ofNeurogenic
Inflammation
Neutral endopeptidase degrades substance
P (13). NEP is located on the surfaces of
cells with substance P receptors, i.e., the
target cells ofsubstance P. Substances that
decrease neutral endopeptidase levels
increase neurogenic inflammation, while
substances that increase neutral endopepti-
dase suppress neurogenic inflammation.
Human recombinant NEP suppresses neu-
rogenic inflammation (18-20). Exogenous
substances that inhibit NEP include ciga-
rette smoke (21), respiratory viruses
(22-25), and the volatile organic chemical
toluene diisocyanate (26).
Possible Roles ofNeurogenic
Inflammation
Neurogenic inflammation may play a role
in a variety ofdisorders, from asthma and
rhinitis to migraine headache, rheumatoid
arthritis, and fibromyalgia. Such a role is
Table 1. Immunogenic versus neurogenic asthma
Immunogenic Neurogenic
Triggered by Protein aeroallergens Volatile organic chemicals
Interacting with IgE antibody Chemical irritant receptors
Located on Mast cells Sensory nerve C-fibers
Releasing Histamine, leukotrienes, Neuropeptides: substance P,
prostoglandins, chemotactic neurokinen A, calcitonin
factors gene-related peptide
Stimulating Sensory nerve C-fibers Mastcell degranulation
Producing Bronchial inflammation Bronchial inflammation
Manifesting as Asthma Asthma
supported by a combination of animal
studies, pharmacological responses ofthese
disorders, and circumstantial evidence. At
the current time these associations are
somewhat speculative, but there is suffi-
cient evidence tojustifyinvestigations.
It is nowknown that the neuropeptides
ofneurogenic inflammation reproduce the
pathology of asthma (27), and the role of
neurogenic inflammation has been docu-
mented in animal models of asthma (28).
Barnes (29) has recently reviewed the cur-
rent evidence for the role of neurogenic
inflammation in asthma and has suggested
strategies for reducing neurogenic inflam-
mation in this disease. It is increasingly
recognized that respiratory irritants such as
VOCs and environmental tobacco smoke
can exacerbate asthma and rhinitis (30-32).
A number ofstudies have documented an
increase in the incidence of asthma in
industrialized countries, over both the long
term and during the 1980s (33). In addi-
tion, studies during the 1980s established
that the American population is exposed to
VOCs in the indoor air (34).
The role of neurogenic inflammation
and chemical irritants in these respiratory
disorders and the upregulation of neuro-
genic inflammation by inhalant irritants
discussed above indicate that there may be
a relationship between indoor air pollution
with VOCs and the worsening asthma epi-
demic. Pursuit ofthis relationship should
be a research priority. In the past asthma
was divided into extrinsic asthma, triggered
by protein aeroallergens, and intrinsic asth-
ma of unknown cause. This distinction
was made before the role of neurogenic
inflammation in asthma was appreciated.
It may be that asthmawould be better clas-
sified as immunogenic or neurogenic
(Table 1). The distinction between neuro-
genic and immunologic asthma is limited
to the catalysts because the two types cross
over after the release ofmediators, in that
the mediators ofneurogenic inflammation
trigger mast cell degranulation, and mast
cell mediators stimulate peripheral nerves.
This "bidirectional regulatory circuit" has
recently been reviewed (35).
This crossover phenomenon does not
mean that neurogenic inflammation and
immunologic inflammation are clinically
identical in all cases. In the upper airways
and skin, the initial complaint associated
with exposure to chemical irritants is burn-
ing or pain, whereas itching is the initial
complaint associated with immune-medi-
ated exposures. It may be that there is
individual variability in the degree to
which crossover is clinically manifested.
The two mechanisms might be differenti-
ated by testing patients with challenging
doses ofantigens and nonallergenic chemi-
cal irritants while monitoring clinical
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symptoms and measuring mediators. This
research would best be carried out by
studying upper airway responses, as nasal
washings can be easily obtained for quanti-
fying mediators.
Another disorder that increased signifi-
cantly during the 1980s is migraine head-
aches (36). Headache is an early and con-
sistent consequence ofexposure to VOCs.
On the basis of pharmaceutical responses
of migraine and animal experiments,
Nicolodi and Sicuteri proposed that neuro-
genic inflammation plays a role in the
pathophysiology of migraine headaches
(37). Silberstein argued that both tension
headaches and migraine may be generated
by neurogenic inflammation (38). Buzzi
and Moskowitz demonstrated that stimula-
tion of trigeminal sensory fibers leads to
changes consistent with those of migraine
in a rat model, and these changes can be
blocked by the antimigraine drugs suma-
triptan and dihydroergotamine (39).
Hardebo has pointed out that the postulate
that neurogenic inflammation mediates
migraine provides a rational explanation
for why serotonin antagonists are effective
in treating migraine (40). Challenge stud-
ies with VOCs on migraine patients, with
and without specific pharmacological
blockage ofrelevant receptors, is needed to
elucidate the role ofneurogenic inflamma-
tion and chemical irritants in migraine.
A comparison ofneuropeptide staining
in the synovium ofpatients with rheuma-
toid arthritis, osteoarthritis, and controls
found weaker staining in the nerve fila-
ments of the rheumatoid arthritis group
(41). The authors suggest that this weaker
staining is evidence of release from nerve
fibers in rheumatoid arthritis, and neuro-
genic inflammation may play a role i9 this
disorder. Zimmerman has suggested that
neurogenic inflammation may play a role
in fibromyalgia (44.
Role ofNeurogenic Inflammation in
ChemicalSensitivity Syndromes
"Sick building syndrome" (SBS) is a term
used to designate an outbreak of illness
associated with indoor air contaminants in
new and tightly sealed buildings. Symp-
toms include irritation of the eyes, nose,
and throat, skin irritation, and neurotoxic
symptoms including mental fatigue and
difficulty concentrating (43). The syn-
drome is an acquired disorder with onset
related to moving into a new or renovated
building, and there is wide individual vari-
ability in onset and symptoms after expo-
sure.
Multiple chemical sensitivity syn-
drome (MCS) is a related syndrome with
onset related to an environmental expo-
sure, most commonly a solvent or pesti-
cide. After the initial exposure, individu-
als become sensitive to low-level chemical
exposures with symptoms involving more
than one organ system. Though this syn-
drome was de-scribed four decades ago
(44.45), it re-mains highly controversial.
Reactive airways dysfunction syn-
drome (RADS) is an asthmalike illness
that develops within minutes to hours
after an acute exposure to dust, smoke, or
solvent. There is persistent bronchial
hyperreactivity with positive methacholine
challenge. The asthma becomes chronic
after the initial exposure and can be diffi-
cult to treat (46).
Figure 3. Chemical sensitivity syndromes. The multiple chemical sensitivity syndrome (MCS), sick build-
ing syndrome (SOS), reactive airways dysfunction syndrome (RADS), the reactive upper airways dysfunc-
tion syndrome.(RUDS) have many features in common. These syndromes may all be disorders ofthe reg-
ulation of neurogenic inflammation.
Reactive upper-airways dysfunction
syndrome (RUDS) also follows a chemical
exposure, and there is persistent chronic
rhinitis. The chief complaint of patients
with RUDS is chemical sensitivity (47).
Unlike patients with RADS, medical atten-
tion is not sought on the day ofexposure,
which probably reflects the fact that
breathing is compromised in RADS but
not in RUDS. Preliminary study of the
nasal mucosa found lymphocytic infil-
trates, and electron microscopy has shown
thickening ofthe basement membrane and
desquamation ofthe respiratory epithelium
(48).
There are many similarities between
SBS, MCS, RADS, and RUDS (Fig. 3). In
each snydrome, a high-dose exposure
induces the syndrome, and subsequent
exacerbations are associated with low-level
exposures. SBS and MCS include symp-
toms involving more than one organ sys-
tem, with the respiratory mucosal and cen-
tral nervous system being prominently
involved. The major difference between
SBS and MCS is that SBS refers to a cluster
of cases associated with a building, while
MCS patients have more generalized com-
plaints. RADS and RUDS have prominent
airway involvement, with the difference
between the two being that RADS involves
the lower airway (asthma), and RUDS
involves the upper airway (rhinitis). In one
small series, 100% ofpatients with RUDS
had extra-airway manifestations and met
the Cullen case definition (49) for MCS.
These syndromes may be related at a
deeper level. All of these illnesses may be
disorders of the regulation of neurogenic
inflammation. The inducing exposure may
alter the respiratory mucosa in one or more
ways. The regulation ofneurogenic inflam-
mation may be disturbed by the depletion
of NEP or other enzymes, which would
result in a heightened response to subse-
quent exposures. The desquamation ofthe
respiratory epithelium seen in RUDS may
remove a barrier to chemical irritants, so
that chemical irritants may reach and trig-
ger the irritant receptors at lower concen-
trations.
Patients with these illnesses complain of
symptoms in organ systems in addition to
the airways, and some patients have no air-
ways symptoms at all. Mechanisms to
explain how airway irritants can trigger sys-
temic symptoms must be considered. First,
it is common for inflammatory illnesses pri-
marily arising in one organ or tissue to pro-
duce systemic manifestations (e.g., the
extra-articular manifestations of rheuma-
toid arthritis and the systemic manifesta-
tions of Crohn's disease). Viral infections
of the upper airway produce systemic
symptoms, including myalgias, fever,
fatigue, and malaise.
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Both the mediators and regulators of
inflammation may be released from the site
of inflammation and affect distant sites.
Two important regulators of inflamma-
tion, interleukin 1 and interleukin 2, sup-
press central nervous system activity
(50,51). Another possibility is that some
form of neural switching may take place.
That is, triggering of chemical irritant
receptors in one organ could lead to an
efferent signal traveling to another site
through an aberrant or conditioned cross-
ing of the pathways. A combination of
these two mechanisms maybe operative.
The hypothesis that neurogenic inflam-
mation is the mechanism ofchemical sen-
sitivity syndromes is amenable to scientific
study. Biopsies ofthe airways ofchemical-
ly sensitive individuals should be abnor-
mal, with signs of inflammation. Im-
munofluorescent monoclonal antibodies
could be used to detect NEP, which
should be decreased, and substance P,
which should be elevated relative to con-
trols. Nasal washings should contain
increased levels ofthe mediators ofneuro-
genic inflammation relative to controls,
and the levels should increase after chemi-
cal challenge in patients but not controls.
Heightened neuronal firing of sensory
fibers should occur after chemical chal-
lenges.
Discussion
Neurogenic inflammation leads to inflam-
mation independent of the immune sys-
tem. Polypeptide mediators are stored in
nerve endings and released when irritant
receptors on nerves are stimulated by
chemicals. The role of neurogenic inflam-
mation in a number ofinflammatory con-
ditions is currently under investigation.
There is strong evidence that neurogenic
inflammation is operative in asthma and
rhinitis..There is circumstantial evidence
that neurogenic inflammation may play a
role in migraine headache. Evidence for a
role in rheumatoid arthritis and fibromyal-
gia is not as compelling at this time. The
significance of these associations for envi-
ronmental health is that neurogenic in-
flammation can be triggered in the airways
by environmental chemicals such as ciga-
rette smoke and solvents. Hence, any dis-
order mediated by neurogenic inflamma-
tion can potentially be exacerbated by
environmental chemicals. Study of the
hypothesis that chemical sensitivity syn-
dromes such as SBS and MCS may result
from neurogenic inflammation arising
from stimulation of irritant receptors by
environmental chemicals may lead to an
understanding of these disorders. It is of
interest that the symptoms of headache,
myalgia, arthralgias and arthritis, and air-
way symptoms reported by MCS patients
overlap with those disorders for which a
role for neurogenic inflammation has been
reported.
The hypothesis that neurogenic inflam-
mation triggered by environmental chemi-
cals plays a role in human health is amen-
able to scientific study. Research should
focus on noninvasive methods for detect-
ing biomarkers of neurogenic inflamma-
tion. Are there degradation products of
substance P or other mediators of neuro-
genic inflammation that are elevated in the
urine or serum of patients with activation
ofthis system? Are there evoked potentials
or nerve conduction parameters that can
be used to detect activation of neurogenic
inflammation? Two groups of patients
should be studied with challenge tests:
patients with disorders in which neuro-
genic inflammation is suspected to play a
role (i.e., asthma, rhinitis, migraine,
rheumatoid arthritis, fibromyalgia) and
patients with chemical sensitivity syn-
dromes. These patients should be isolated
from VOCs in a specially constructed din-
ical research unit and monitored for reso-
lution oftheir symptoms. Chemical chal-
lenges should be conducted while patients
are monitored for provoked symptoms.
Biomarkers of neurogenic inflammation
should be measured throughout the course
ofthese challenges.
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